Drug Trial Radar · NCT05857163
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
700
Actual
Start
May 18, 2023
Primary completion
Dec 24, 2023
Study completion Mar 26, 2024
Sponsor
- Lead sponsor
- TenNor Therapeutics (Suzhou) LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.
Conditions
- H.Pylori Infection
Interventions
Rifasutenizol capsulesDrug
400 mg, BID, taken orally within half an hour after breakfast and dinner.
Rabeprazole sodium enteric-coated tabletsDrug
20 mg, BID, taken orally within half an hour before breakfast and dinner.
Amoxicillin CapsulesDrug
1 g, BID, taken orally within half an hour after breakfast and dinner.
Clarithromycin placebo tabletsDrug
BID, taken orally within half an hour after breakfast and dinner.
Bismuth potassium citrate placebo capsulesDrug
BID, taken orally within half an hour before breakfast and dinner.
Clarithromycin tabletsDrug
500 mg, BID, taken orally within half an hour after breakfast and dinner.
Bismuth potassium citrate capsulesDrug
240 mg, BID, taken orally within half an hour before breakfast and dinner.
Rifasutenizol placebo capsulesDrug
BID, taken orally within half an hour before breakfast and dinner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication Rate of H.Pylori InfectionTime frame: 4 to 6 weeks after the last dose of the study drugs
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.